SHIRE PLC - Updated Rule 2.10 Announcement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR
   FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
                      RELEVANT LAWS OF SUCH JURISDICTION.

                        Updated Rule 2.10 Announcement

Dublin, Ireland - July 30, 2014 - In accordance with Rule 2.10 of The City Code
on Takeovers and Mergers, Shire plc (LSE: SHP, NASDAQ: SHPG) confirms that, as
at close of business on July 29, 2014, it had in issue 589,534,715 ordinary
shares of 5 pence each (excluding ordinary shares held in treasury), with ISIN
JE00B2QKY057, which carry voting rights of one vote per share.

Shire plc has an American Depositary Receipt program for which Citibank, N.A.
acts as Depositary. One American Depositary Share ("ADS") represents three
ordinary shares of 5 pence each, with ISIN US82481R1068. The ADSs trade on the
NASDAQ Global Select Market.

For further information please contact:

Investor Relations

Jeff Poulton                            [e-mail]   [phone]

Sarah Elton-Farr                        [e-mail] [phone]

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases,
Gastrointestinal, and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmology.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release

www.shire.com